1
|
Lyu L, Xiang W, Zheng F, Huang T, Feng Y, Yuan J, Zhang C. Significant Prognostic Value of the Autophagy-Related Gene P4HB in Bladder Urothelial Carcinoma. Front Oncol 2020; 10:1613. [PMID: 32903592 PMCID: PMC7438560 DOI: 10.3389/fonc.2020.01613] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2020] [Accepted: 07/24/2020] [Indexed: 01/01/2023] Open
Abstract
While hundreds of consistently altered autophagy-related genes (ARGs) have been identified in cancers, their prognostic value in bladder urothelial carcinoma (BUC) remains unclear. In the present study, we collected 232 ARGs from the Human Autophagy Database (HADb), and identified 37 differentially expressed ARGs in BUC based on The Cancer Genome Atlas (TCGA) database. Kaplan-Meier survival analysis based on the Gene Expression Profiling Interactive Analysis (GEPIA) database revealed that among the 37 differentially expressed ARGs, prolyl 4-hydroxylase, beta polypeptide (P4HB), and regulator of G protein signaling 19 (RGS19) were significantly negatively correlated with overall survival (OS) and disease-free survival (DFS). Overexpression of P4HB and RGS19 in BUC was further validated using independent data sets, including those from the Oncomine and Gene Expression Omnibus (GEO) databases. cBioPortal and UALCAN analyses indicated that altered P4HB and RGS19 mRNA expression was significantly associated with mutations and clinical characteristics (nodal metastasis and cancer stage). Moreover, co-expression network analysis and gene set enrichment analysis (GSEA) predicted that the potential functions of P4HB and RGS19 are involved in the endoplasmic reticulum (ER) stress response, cytokine-mediated signaling pathway and inflammatory response. More importantly, multivariate Cox proportional hazards regression analysis demonstrated that P4HB, but not RGS19, is an independent and unfavorable BUC biomarker based on clinical characteristics (age, gender, cancer stage, and pathological TNM stage). Finally, we validated that the mRNA and protein expression levels of P4HB were upregulated in four bladder cancer cell lines (T24, J82, EJ, and SW780) and found that knockdown of P4HB dramatically inhibited the invasion and proliferation of bladder cancer cells. In summary, our study screened ARGs and identified P4HB as a biomarker that can predict the progression and prognosis of BUC and may provide a better understanding of the autophagy regulatory mechanisms involved in BUC.
Collapse
Affiliation(s)
- Lei Lyu
- Department of Urology, Wuhan No.1 Hospital, Huazhong University of Science and Technology, Wuhan, China
| | - Wei Xiang
- Department of Urology, Wuhan No.1 Hospital, Huazhong University of Science and Technology, Wuhan, China
| | - Fuxin Zheng
- Department of Urology, Wuhan No.1 Hospital, Huazhong University of Science and Technology, Wuhan, China
| | - Tao Huang
- Department of Urology, Wuhan No.1 Hospital, Huazhong University of Science and Technology, Wuhan, China
| | - Yan Feng
- Department of Pathology, Wuhan No.1 Hospital, Huazhong University of Science and Technology, Wuhan, China
| | - Jingdong Yuan
- Department of Urology, Wuhan No.1 Hospital, Huazhong University of Science and Technology, Wuhan, China
| | - Chuanhua Zhang
- Department of Urology, Wuhan No.1 Hospital, Huazhong University of Science and Technology, Wuhan, China
| |
Collapse
|
2
|
Gu Y, Lu J, Chen C, Zheng F. NEDD9 overexpression predicts poor prognosis in solid cancers: a meta-analysis. Onco Targets Ther 2019; 12:4213-4222. [PMID: 31213839 PMCID: PMC6549757 DOI: 10.2147/ott.s205760] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2019] [Accepted: 04/26/2019] [Indexed: 12/24/2022] Open
Abstract
Background: The oncogenicity of neural precursor cell-expressed developmentally down-regulated 9 (NEDD9) has been demonstrated in multiple cancer types. However, the prognostic value of NEDD9 in some solid cancers remains controversial. Thus, this meta-analysis was conducted to evaluate the relationship between NEDD9 expression survival rates in solid tumors. Method: Our meta-analysis included studies searched from various search engines with specific inclusion criteria and exclusion criteria. Combined HRs for overall survival (OS) and disease-free survival (DFS) or progression-free survival (PFS) or recurrence-free survival (RFS) or cancer-specific survival (CSS) were assessed using fixed-effects and random-effects models. The source of heterogeneity was identified by subgroup analysis. Additionally, publication bias was assessed using funnel plot and Egger’s regression asymmetry test. Result: Eighteen studies with a total of 2,476 patients were retrieved for analysis. Pooled HRs and 95% CIs were calculated. Both OS (HR=1.82; 95% CI: 1.43–2.31) and DFS/PFS/RFS/CSS (HR=2.54; 95% CI: 1.93–3.33) indicated that NEDD9 overexpression is associated with poor OS in cancer patients with solid tumors. Conclusion: NEDD9 overexpression might be a potential marker to predict prognosis in solid cancer patients.
Collapse
Affiliation(s)
- Yang Gu
- Department of Orthopedics, The Affiliated Union Hospital of Fujian Medical University, Fuzhou, People's Republic of China
| | - Jingjing Lu
- Department of Gynecology, Hwa Mei Hospital, University of Chinese Academy of Sciences (Ningbo No.2 Hospital), Ningbo, People's Republic of China
| | - Chen Chen
- Department of Orthopedics, First Affiliated Hospital of Xiamen University, Xiamen, People's Republic of China
| | - Fei Zheng
- Department of Gynecology, Hwa Mei Hospital, University of Chinese Academy of Sciences (Ningbo No.2 Hospital), Ningbo, People's Republic of China
| |
Collapse
|
3
|
Li X, Jiang F, Wang X, Gu X. SPAG9 regulates HEF1 expression and drives EMT in bladder transitional cell carcinoma via rac1 signaling pathway. Am J Cancer Res 2018; 8:2467-2480. [PMID: 30662804 PMCID: PMC6325469] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2018] [Accepted: 11/29/2018] [Indexed: 06/09/2023] Open
Abstract
Recently SPAG9 has been reported to show aberrant expressions in numerous human malignancies and act as a crucial role in tumor's proliferation and invasion. Human enhancer of filamentation 1 (HEF1, also known as CasL and NEDD9) is a non-catalytic scaffolding protein belonging to CAS (Crk-associated substrate) protein family that interacts with multiple signaling cascades. Due to the diversified function of HEF1, abnormal expression of HEF1 frequently combines with malignant phenotypes and poor prognosis. However, little is known between the relationship of SPAG9 and HEF1 in bladder tumorigenesis. In this study, expression of SPAG9 in vivo and in vitro has been detected by quantitative real-time PCR and Western blot analysis after transfected with SPAG9 overexpression/inhibitor vector. We also found that HEF1 expression shows consistency and is regulated by SPAG9. Overexpression of SPAG9 promotes bladder cancer cells migration through HEF1 upregulation and emerges protein level of activated Rac1. Silencing SPAG9 inhibits cell migration through HEF1 downregulation and reduces protein level of activated Rac1. Also, we found that expression of EMT marker such as E-cadherin, Vimentin is regulated by SPAG9. Considering EMT plays a crucial role in tumor cells spreading and invasion, SPAG9 and HEF1 may potentially set a new therapeutic approach to bladder cancer treatment.
Collapse
Affiliation(s)
- Xu Li
- Department of Urology, China-Japan Union Hospital of Jilin UniversityChangchun 130033, Jilin, China
| | - Fuquan Jiang
- Department of Urology, China-Japan Union Hospital of Jilin UniversityChangchun 130033, Jilin, China
| | - Xinsheng Wang
- Department of Urology, Tianjin First Center HospitalTianjin 300000, China
| | - Xinquan Gu
- Department of Urology, China-Japan Union Hospital of Jilin UniversityChangchun 130033, Jilin, China
| |
Collapse
|
4
|
Zhang Q, Wang H, Wei H, Zhang D. Focal adhesion kinase (FAK) is associated with poor prognosis in urinary bladder carcinoma. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY 2018; 11:831-838. [PMID: 31938172 PMCID: PMC6958047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 08/27/2017] [Accepted: 11/13/2017] [Indexed: 06/10/2023]
Abstract
OBJECTIVE Overexpression of the enhancer of focal adhesion kinase (FAK) protein, an intracellular tyrosine kinase protein, has been reported to be associated with biological malignancy of gastric cancer and several other tumors. The purpose of this study was to examine the expression of FAK and analyze its correlation with the clinicopathological features of human urinary bladder carcinoma. METHODS 315 archived cases of urinary bladder carcinoma were reviewed and TMAs were developed as per established procedures. Immunohistochemical staining for FAK was performed to assess the correlation between the expression profiles and the clinicopathological parameters and clinical outcome. RESULTS Protein level of FAK was up-regulated in urinary bladder carcinoma compared with adjacent non-tumor tissues. Overexpression of FAK was significantly associated with high histologic grade, angiolymphatic invasion, lymph node metastasis, myometrial invasion and cervical involvement (P < 0.05). Further multivariate analysis suggested that expression of FAK was independent prognostic indicator for urinary bladder carcinoma. These alterations in expression were also associated with greater risk of disease progression and decreased chance of carcinoma-specific survival. Kaplan-Meier analysis demonstrates that overexpression of FAK was significantly associated with decreased overall survival. CONCLUSION Overexpression of FAK corelates with well established pathologic risk factors and may predict more aggressive biologic behavior in urinary bladder carcinoma. The expression patterns of FAK correlated well with the pathologic stage, disease progression, and carcinoma-specific survival. This finding may aid in identifying more biologically aggressive carcinomas and thus patients who could benefit from more intensive adjuvant therapy.
Collapse
Affiliation(s)
- Qi Zhang
- Department of Urology, Zhejiang Provincial People’s HospitalHangzhou, China
- People’s Hospital of Hangzhou Medical CollegeHangzhou, China
- Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine of Zhejiang ProvinceHangzhou, China
| | - Huiju Wang
- People’s Hospital of Hangzhou Medical CollegeHangzhou, China
- Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine of Zhejiang ProvinceHangzhou, China
| | - Haibing Wei
- Department of Urology, Zhejiang Provincial People’s HospitalHangzhou, China
- People’s Hospital of Hangzhou Medical CollegeHangzhou, China
| | - Dahong Zhang
- Department of Urology, Zhejiang Provincial People’s HospitalHangzhou, China
- People’s Hospital of Hangzhou Medical CollegeHangzhou, China
- Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine of Zhejiang ProvinceHangzhou, China
| |
Collapse
|
5
|
The Prognostic Role of NEDD9 and P38 Protein Expression Levels in Urinary Bladder Transitional Cell Carcinoma. JOURNAL OF ONCOLOGY 2017; 2017:6095205. [PMID: 28194179 PMCID: PMC5282419 DOI: 10.1155/2017/6095205] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/17/2016] [Revised: 10/15/2016] [Accepted: 10/18/2016] [Indexed: 11/18/2022]
Abstract
Background. The most common malignant tumor of the urinary bladder is transitional cell carcinoma (TCC). Neural precursor cell-expressed developmentally downregulated protein 9 (NEDD9) is found to be a cell adhesion mediator. P38 Mitogen-Activated Protein Kinase is a serine/threonine kinases member which can mediate carcinogenesis through intracellular signaling. Methods. To assess their prognostic role; NEDD9 and p38 protein were evaluated in sections from 50 paraffin blocks of TCC. Results. The high expressions of NEDD9 and p38 protein were significantly associated with grade, stage, distant metastasis (p < 0.001), number of tumors, lymph node metastasis, and tumor size (p < 0.001, 0.002; 0.018, <0.001; and 0.004, 0.007, respectively). High NEDD9 and p38 detection had a worse 3-year OS (p = 0.041 and <0.001, respectively). By multivariate analysis the NEDD9 and p38 protein expression levels and various clinicopathological criteria including gender, grade, stage of the tumor, and regional lymph node involvement were independent prognostic parameters of TCC of the urinary bladder patients' outcome. Conclusion. NEDD9 and p38 protein expressions were poor prognostic markers of TCC.
Collapse
|
6
|
Li M, Yan S, Cai M, Lu J, Zhang M, Yang P, Luo R. High expression of HEF1 predicts a poorer prognosis of hepatocellular carcinoma: A retrospective study. Mol Clin Oncol 2016; 4:159-165. [PMID: 26893853 DOI: 10.3892/mco.2015.707] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2015] [Accepted: 12/08/2015] [Indexed: 11/05/2022] Open
Abstract
Human enhancer of filamentation 1 (HEF1), a scaffold protein, is highly expressed in a variety of cancer types and is involved cancer cell growth, migration and invasion. The prognostic value of HEF1 in hepatocellular carcinoma (HCC) remains to be elucidated. The aim of the present study was to assess the association between the expression of HEF1, the clinical/pathological parameters and survival in HCC. In the present study, immunohistochemistry was performed to investigate the protein expression of HEF1 in 123 hepatocellular carcinoma tissues and their adjacent normal liver tissues. Spearman's rank correlation, Kaplan-Meier plots and Cox regression model were used to analyze the data. Overexpression of HEF1 protein was observed in HCC tissue when compared with their adjacent non-malignant liver tissue. High expression of HEF1 correlated with higher advanced tumor, node, metastasis (TNM) stage and vascular invasion (P<0.05). In univariate and multivariate analysis, the expression of HEF1 was identified as an independent prognostic factor in the 123 patients with HCC. In subgroup analysis, high expression of HEF1 correlated with a poorer prognosis in advanced (TNM III+IV) stages (P<0.05). These findings demonstrated the potential value of detecting the expression of HEF1 by immunohistochemistry as a prognostic biomarker and therapeutic target for patients with HCC.
Collapse
Affiliation(s)
- Mei Li
- Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 510060, P.R. China
| | - Shumei Yan
- Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 510060, P.R. China
| | - Muyan Cai
- Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 510060, P.R. China
| | - Jiabin Lu
- Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 510060, P.R. China
| | - Meifang Zhang
- Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 510060, P.R. China
| | - Ping Yang
- Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 510060, P.R. China
| | - Rongzhen Luo
- Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 510060, P.R. China
| |
Collapse
|